In this context, lipid-encapsulated nanoparticles containing double-stranded small interfering RNA (siRNA) have been applied for binding to transthyretin (TTR) mRNA causing degradation of TTR deposits present in patients with hereditary TTR-mediated amyloidosis [2]. This evidence concerns the gene TTR and amyloidosis.